Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

 

Q419 figures are as at 31/01/2020

FY2019-2023 figures are as at 31/01/2020

Please select...
£m (unless stated) Q419 Q419 n= 2019 2020 2021 2022 2023 2019-2023 n=
Turnover 9,001 15 33,856 35,132 36,383 37,820 39,330 15
Cost of sales (2,774) 15 (10,005) (10,359) (10,707) (11,050) (11,406) 15
Selling, general and administration (2,917) 15 (10,515) (10,867) (11,106) (11,367) (11,659) 15
Research and Development (1,243) 15 (4,418) (4,777) (4,976) (5,157) (5,334) 15
Royalty income 82 15 351 364 374 380 380 15
Operating profit 2,149 15 9,269 9,492 9,967 10,627 11,311 15
Net finance costs (253) 15 (866) (870) (829) (798) (761) 15
Associates 1 15 71 26 26 26 26 15
Profit before tax 1,897 15 8,474 8,649 9,164 9,855 10,576 15
Taxation (329) 15 (1,440) (1,571) (1,727) (1,887) (2,019) 15
Profit after tax 1,568 15 7,034 7,078 7,437 7,969 8,556 15
Minority interests (294) 15 (856) (1,166) (1,232) (1,302) (1,353) 15
Profit attributable to shareholders 1,274 15 6,178 5,912 6,205 6,666 7,203 15
WANS (m) 4,937 15 4,943 4,960 4,977 4,995 5,012 15
Earnings per share (p) 25.8 15 125.0 119.2 124.7 133.5 143.7 15
Dividend per share (p) 23.0 15 80.0 80.0 80.1 80.3 81.4 13
Free Cash Flow n/a n/a 3,270 5,021 5,229 5,834 6,422 10
Net Debt n/a n/a (25,529) (23,454) (22,303) (20,563) (18,286) 12

The firms included are: Bank of America, Barclays, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Leerink , Morgan Stanley, Redburn, UBS, Wolfe Research

Turnover £m Q419 Q419 n= 2019 2020 2021 2022 2023 2019-2023 n=
Anoro 150 15 523 558 595 622 645 15
Arnuity 14 15 47 50 53 56 58 15
Incruse 72 15 257 269 284 299 313 15
Relvar/Breo 275 15 977 982 1,003 1,018 1,029 15
Trelegy 167 15 513 792 1,041 1,248 1,415 15
Ellipta portfolio 678 15 2,317 2,651 2,977 3,243 3,459 15
Nucala 215 15 765 896 998 1,076 1,141 15
Total Respiratory 3,082 15 3,082 3,547 3,975 4,320 4,600 15
                 
Tivicay 434 13 1,670 1,591 1,532 1,469 1,411 13
Triumeq 630 13 2,541 2,314 2,170 2,053 1,958 13
Juluca 115 13 370 519 615 682 727 13
Dovato 32 13 55 266 496 717 882 13
Dolutegravir based regimens 1,211 15 4,636 4,672 4,780 4,875 4,924 15
Cabotegravir +/- rilpivirine - - - 28 121 244 373 15
fostemsavir - - - 29 95 150 203 13
Epzicom/Kivexa 18 15 78 58 47 39 33 15
HIV 1,272 15 4,869 4,916 5,140 5,379 5,589 15
                 
Benylsta 175 15 618 707 788 853 884 15
                 
Zejula 74 15 237 384 542 690 849 15
                 
Advair (US) 107 15 505 263 185 152 129 15
Seretide (ex US) 305 15 1,223 1,069 955 863 784 15
Seretide/Advair 412 15 1,728 1,332 1,140 1,016 913 15
Flixotide/Flovent 138 15 581 524 490 460 433 15
Ventolin 244 15 956 740 675 642 616 15
Avamys/Veramyst 74 15 326 332 338 340 311 15
Established Respiratory 929 15 3,864 3,188 2,895 2,701 2,508 15
Other Established Pharmaceuticals 1,262 15 4,930 4,618 4,393 4,200 4,017 15
Established Pharmaceuticals 2,191 15 8,794 7,806 7,287 6,902 6,525 15
                 
belantamab mafodotin (GSK'916 BCMA) - - - 46 199 375 584 15
dostarlimab - - - 20 67 119 180 11
daprodustat - - - 0 19 77 166 14
                 
Pharmaceuticals 4,606 15 17,602 17,423 18,015 18,770 19,558 15

The firms included are: Bank of America, Barclays, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Leerink , Morgan Stanley, Redburn, UBS, Wolfe Research

Turnover £m Q419 Q419 n= 2019 2020 2021 2022 2023 2019-2023 n=
Bexsero 125 14 692 751 808 852 888 14
Menveo 48 14 249 252 259 267 275 14
Fluarix/Flulaval 162 15 565 565 583 600 617 15
Shingrix 475 15 1,753 2,035 2,269 2,499 2,773 15
Boostrix 137 14 591 596 611 623 636 14
Cervarix 30 14 93 90 91 92 93 14
Hepatitis 202 14 881 879 894 912 926 14
Infanrix, Pediarix 159 14 736 717 724 731 738 14
Rotarix 131 14 548 553 565 577 589 14
Synflorix 101 14 445 439 440 438 434 14
Vaccines 1,727 15 7,142 7,376 7,765 8,137 8,541 15

The firms included are: Bank of America, Barclays, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Leerink , Morgan Stanley, Redburn, UBS, Wolfe Research

Turnover £m Q419 Q419 n= 2019 2020 2021 2022 2023 2019-2023 n=
Consumer Health* 2,664 15 9,088 10,328 10,602 10,912 11,230 15

* Due to the Consumer Healthcare JV with Pfizer, the categories are inconsistently forecasted and have therefore been excluded. 

The firms included are: Bank of America, Barclays, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Jefferies, JP Morgan, Leerink , Morgan Stanley, Redburn, UBS, Wolfe Research

Back to top